Burrill Starts Sarepta (SRPT) at Market Outperform; Sees Plenty of Upside in DMD Space
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Burrill Starts Sarepta Therapeutic (SRPT) at Market Outperform
November 26, 2012 9:56 AM ESTBurrill initiates coverage on Sarepta Therapeutic (NASDAQ: SRPT) with a Market Outperform. PT $54.00.
For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.
Shares of Sarepta Therapeutic closed at $29.35 yesterday, with a 52 week range of $3.30-$45.00.... More
